| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $992,385 ) |
| | 2025 | 2025 | ALVEOLUS BIO, INC. | 1500 1ST AVE N, SUITE H102 | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 001 | 4 | NIH | 4/14/2025 | $992,385 |
| | 2025 | 2023 | ALVEOLUS BIO, INC. | 1500 1ST AVE N, SUITE H102 | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 000 | 2 | NIH | 2/14/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $999,425 ) |
| | 2024 | 2024 | ALVEOLUS BIO, INC. | 1500 1ST AVE N, SUITE H102 | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 001 | 3 | NIH | 2/21/2024 | $999,425 |
|
| Issue Date FY: 2023 ( Subtotal = $3,297 ) |
| | 2023 | 2023 | ALVEOLUS BIO, INC. | 1500 1ST AVE N, SUITE H102 | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 003 | 2 | NIH | 9/8/2023 | $3,297 |
|
|
